Omeros (NASDAQ:OMER) Trading 6.4% Higher – What’s Next?

Omeros Co. (NASDAQ:OMER) shares were up 6.4% during trading on Thursday . The stock traded as high as $8.96 and last traded at $9.07. Approximately 309,440 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 530,454 shares. The stock had previously closed at $8.52.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, January 17th. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Performance

The stock has a market capitalization of $490.84 million, a PE ratio of -3.67 and a beta of 2.03. The business’s 50-day moving average price is $8.69 and its 200 day moving average price is $7.49.

Hedge Funds Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP grew its stake in Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after buying an additional 13,201 shares in the last quarter. ProShare Advisors LLC raised its position in Omeros by 75.0% during the fourth quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 7,927 shares in the last quarter. Nomura Holdings Inc. lifted its stake in Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after purchasing an additional 430,932 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Omeros by 46.2% in the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after purchasing an additional 27,088 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,110 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.